Form 4: MindMed Director Carol Vallone Granted Stock Options Valued at $7.3 Per Share

Mind Medicine (MindMed) Inc. Director Carol A. Vallone was granted 75,187 stock options with an exercise price of $7.3 per share, aligning her interests with shareholder value.

Summary

• Carol A. Vallone, a Director of Mind Medicine (MindMed) Inc. (MNMD), was granted 75,187 stock options.
• The options have an exercise price of $7.3 per share.
• The grant date for these options was June 12, 2025.
• The options expire on June 11, 2035.
• The stock options vest and become exercisable as to 1/12th of the underlying shares on each monthly anniversary of the grant date.
• An accelerated vesting clause states that if the Company's annual meeting immediately following the grant date occurs prior to the first anniversary, the options will vest immediately prior to that annual meeting, subject to continued service.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates alignment of director's interests with shareholders through equity compensation, a standard and generally well-regarded practice.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value only if the company's stock price increases.
• Equity compensation is a standard practice to attract and retain experienced board members.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the vesting schedule of the granted options.

Industry Context

The granting of stock options to directors is a common form of equity compensation across various industries, including the biotechnology and pharmaceutical sectors, to incentivize long-term performance and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule (monthly over a period, with potential acceleration upon annual meeting) is a typical structure designed to retain directors and incentivize sustained service.
• The exercise price being set at the market price on the grant date is standard for incentive stock options.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with the company's stock performance, potentially benefiting shareholders if the stock price increases.
• Employees/Management: This transaction is specific to a director's compensation and does not directly impact other employees or management, though it reflects the company's compensation philosophy.

Next Steps

• The stock options will begin vesting on a monthly basis from June 12, 2025, or potentially earlier if the company's annual meeting occurs before the first anniversary of the grant date.

Key Dates

Keywords

Mind Medicine, MNMD, SEC Form 4, Stock Option Grant, Director Compensation, Equity Compensation, Insider Transaction, Carol Vallone